Syndax Pharmaceuticals Inc. filed for an initial public offering (IPO) Friday under the Jumpstart Our Business Startups Act of 2012. The oncology-focused biotech with an FDA breakthrough designation for its lead program, entinostat, plans to use proceeds from the Nasdaq offering to support trials of the therapeutic and a new drug application for its use in treating metastatic breast cancer.